This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Walsh, S.
Right arrow Articles by Mond, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Walsh, S.
Right arrow Articles by Mond, J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, February 2003, p. 554-558, Vol. 47, No. 2
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.2.554-558.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Improved Pharmacokinetics and Reduced Antibody Reactivity of Lysostaphin Conjugated to Polyethylene Glycol

Scott Walsh,* Anjali Shah, and James Mond

Biosynexus, Inc., Gaithersburg, Maryland 20877

Received 1 May 2002/ Returned for modification 4 September 2002/ Accepted 8 November 2002

Lysostaphin is a 27-kDa endopeptidase that enzymatically disrupts the cell wall of Staphylococcus aureus and is a promising candidate for treating S. aureus blood-borne infections. It would be extremely useful to define conditions that would both increase lysostaphin's in vivo half-life to allow for more effective tissue distribution and reduce its immunogenicity. Conjugation of polyethylene glycol (PEG) to lysostaphin (PEGylation) was investigated as a means to accomplish these goals. Rather than using linear forms of PEG, branched PEGs were chosen as the initial candidates because their large spatial volumes prevent entry of the polymer into the enzyme's active sites, which could potentially reduce enzymatic function. Enzymatic activity for most PEGylated lysostaphins was reduced, but these compounds were still considerably active compared to unconjugated lysostaphin, with conjugates that had lower degrees of PEG modification having greater activity than those with higher degrees. PEGylated lysostaphin injected intravenously had a serum drug half-life of up to 24 h and resulted in much higher plasma drug concentrations than an equal dose of unconjugated lysostaphin, which had a half-life of less than 1 h. Finally, reduced binding affinity was shown for PEGylated lysostaphin in an antilysostaphin capture enzyme-linked immunosorbent assay, with some PEG-lysostaphin conjugates having binding affinities that were reduced more than 10-fold compared to unconjugated lysostaphin. These findings demonstrate that PEGylation of lysostaphin, while diminishing its S. aureus killing activity, results in prolonged serum drug persistence and reduced antibody binding. These features should significantly enhance lysostaphin's therapeutic value as an intravenous "antibiotic" against S. aureus.

* Corresponding author. Mailing address: Biosynexus, Inc., 9119 Gaither Rd., Gaithersburg, MD 20877. Phone: (301) 987-1171. Fax: (301) 990-4990. E-mail: scottwalsh{at}biosynexus.com.

Antimicrobial Agents and Chemotherapy, February 2003, p. 554-558, Vol. 47, No. 2
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.2.554-558.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Koprivnjak, T., Weidenmaier, C., Peschel, A., Weiss, J. P. (2008). Wall Teichoic Acid Deficiency in Staphylococcus aureus Confers Selective Resistance to Mammalian Group IIA Phospholipase A2 and Human {beta}-Defensin 3. Infect. Immun. 76: 2169-2176 [Abstract] [Full Text]  
  • Kokai-Kun, J. F., Chanturiya, T., Mond, J. J. (2007). Lysostaphin as a treatment for systemic Staphylococcus aureus infection in a mouse model. J Antimicrob Chemother 60: 1051-1059 [Abstract] [Full Text]  
  • Wu, Z., Li, Z.-B., Chen, K., Cai, W., He, L., Chin, F. T., Li, F., Chen, X. (2007). microPET of Tumor Integrin {alpha}v{beta}3 Expression Using 18F-Labeled PEGylated Tetrameric RGD Peptide (18F-FPRGD4). JNM 48: 1536-1544 [Abstract] [Full Text]  
  • Oluola, O., Kong, L., Fein, M., Weisman, L. E. (2007). Lysostaphin in Treatment of Neonatal Staphylococcus aureus Infection. Antimicrob. Agents Chemother. 51: 2198-2200 [Abstract] [Full Text]  
  • Borysowski, J., Weber-Dabrowska, B., Gorski, A. (2006). Bacteriophage endolysins as a novel class of antibacterial agents.. Exp. Biol. Med. 231: 366-377 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»